Live
Endpoints NewsNew home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drugClinical OMICsBrain-Controlled Hearing Aid Singles Out Voices in a CrowdBioWorldBiggest gainers and losers for May 4-8, 2026Endpoints NewsInhibrx says combo therapy shrank more tumors than Merck's Keytruda aloneFierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase dataFierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year planBioPharma DiveInhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialFDA News ReleasesFDA Advances Drug Repurposing to Address Unmet Medical NeedsEndpoints NewsBraveheart Bio's Hengrui-licensed cardiac drug scores second clinical winBioPharma DiveBiotech layoffs are easing, but is the worst over?FierceBiotechNovo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotechBioWorldShanghai Jeyou Pharmaceutical patents LGALS3 inhibitors
This story is not available in the archive.